Clinical Trials Logo

Catamenial Epilepsy clinical trials

View clinical trials related to Catamenial Epilepsy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05201703 Recruiting - Catamenial Epilepsy Clinical Trials

Fycompa in Catamenial Epilepsy

Start date: March 9, 2022
Phase: Phase 4
Study type: Interventional

The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated excitotoxicity. This mechanism of action would allow a novel use of perampanel as an effective treatment of C1 catamenial epilepsy.